Representative Investments

Genmab.svg

Role: Co-Founder

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and autoimmune diseases, based on proprietary next generation antibody technologies.

Ticker: GEN.CO – Market cap: 71.9 bln. DKK

Biomarin

Role: Seed investor

BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for rare diseases driven by genetic causes. BioMarin’s core business is in enzyme replacement therapies.

Ticker: BMRN – Market cap: 13.1 bln. USD

logo

Role: Pro-management activist public investor

Facet Biotech Corporation was a biotechnology company engaged in the identification and development of oncology drugs. Facet was formed as a spin-off of the biotechnology segment of PDL BioPharma, Inc.

Acquired by Abbott Laboratories Inc. for 450 mil. USD

logo

Role: Founder

Forward Pharma A/S is a NASDAQ traded biotechnology company, founded in 2005 in Copenhagen, Denmark. The company is focused on the immunomodulatory compound dimethyl fumarate for the treatment of immune diseases.

Ticker: FWP – Market cap: 859.6 mil. USD

Acadia

Role: Co-founder

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

Ticker: ACAD – Market cap: 3.8 bln. USD

Elan logo368_281 copy 20111

Role: Pro-management activist public investor

Élan Corporation PLC was a major drug firm, with a focus in neurology and autoimmune diseases such as rheumatid arthritis, multiple sclerosis and inflammatory bowel disease. In February 2013 Élan sold the rights to their drug Tysabri to Biogen Idec for 3.25 bln. USD.

Acquired by Perrigo for 8.6 bln. USD

The above stated investments were made by CEO Florian Schönharting at NB Capital in investment funds advised by NB Capital/Florian Schönharting or in his prior tenure at an asset management company. Note that some of them may have changed names since the point of investment. In this case the new name is listed.

nb capital

About Us

 

NB Capital was seeded in 2001 by a small group of highly experienced biotech investors and a pharmaceutical company. Since the beginning we have been focused on investing capital in public and private equity markets using principles of risk aversion and innovation.

The Team

Florian Schönharting

Florian Schönharting, CEO and founder of NB Capital, has more than 25 years of investment experience in the biotech and pharmaceuticals sector. Schönharting was the founder of the highly successful Genmab during his tenure at BankInvest.

Cora Madsen

Cora Madsen is Director of NB Public Equity and former CFO of Nordic Biotech Advisors. Previously, she held senior managerial positions in international financial corporations such as Schroder and the Chase Manhattan Bank.

Theis Terwey, MD

With a past at Memorial Sloan-Kettering and Charité, Theis Terwey, MD, Partner at NB Capital, leads NB Capital’s multifaceted team of medical, regulatory, IP, and financial experts and directs the due diligence process.

Magnus C. Halle

Magnus C. Halle is the Personal Assistant to Florian Schönharting. Currently enrolled at the Copenhagen Business School in the BSc of Economics and Business Administration program.

nb capital

Past Investments

 

bfs2I-Vd

Investment type: Public Equity

Ticker: ATLN – Market cap: 15.9 bln. CHF

Pharmacyclics-logo

Investment type: Public Equity

Acquired by AbbVie Inc. for 21 bln. USD

logo

Investment type:
Founder

Ticker: FWP – Market cap: 859.6 mil. USD

Elan logo368_281 copy 20111

Investment type:
Pro-management Activist Public Investment

Acquired by Perrigo for 8.6 bln. USD

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

Investment type:
Public

Ticker: PDLI – Market cap: 525 mil. USD

Zymenex-Logo

Investment type:
Seed Investment (lead-investor)

Acquired by Chiesi Group for an undisclosed amount

fibrogen-Logo

Investment type:
Public

Ticker: FGEN – Market cap: 1.1 bln. USD

Biogen-Logo

Investment type:
Early Public

Ticker: BIIB – Market cap: 53.5 bln. USD

Janssen-Logo

Investment type:
Early Public

Merged with Johnson & Johnson, now a subsidiary.

Chiron Corp

Investment type:
Early Public

Acquired by Novartis for 5.4 bln. USD (Novartis already owned ~50%)

imgn-logo

Investment type:
Early Public

Ticker: IMGN – Market cap: 262.4 mil. USD

Regeneron-Pharmaceuticals-Inc-logo

Investment type:
Early Public

Ticker: REGN – Market cap: 39.2 bln. USD

amylin-pharmaceuticals-logo

Investment type:
Early Public

Acquired by Bristol-Myers Squibb for 5.3 bln. USD

logo_cephalon_p_rgb-logo

Investment type:
Public

Acquired by Teva for 6.8 bln. USD

Gilead_Sciences_Logo.svg

Investment type:
Early Public

Ticker: GILD – Market cap: 112.9 bln. USD

MedImmune_logo

Investment type:
Public

Acquired by AstraZeneca for 15.2 bln. USD

free-vector-interneuron-pharmaceuticals_082796_interneuron-pharmaceuticals-logo

Investment type:
Early Public

Acquired by Endo for 370 mil. USD

scios-logo

Investment type:
Early Public

Acquired by Johnson & Johnson for 2.4 bln. USD

Genzyme-Logo

Investment type:
Early Public

Acquired by Sanofi for 20.1 bln. USD

biochem_pharma_logo_28080

Investment type:
Early Public

Acquired by Shire Plc for 4.5 bln. EUR

Vertex-Logo

Investment type:
Early Public

Ticker: VRTX – Market cap: 21.9 bln. USD

1000px-Genentech.svg-logo

Investment type:
Early Public

Acquired by F-Hoffmann-La Roche AG for 46.8 bln. USD

Genmab.svg

Investment type:
Founder

Ticker: GEN.CO – Market cap: 71.9 bln. DKK

Biomarin

Investment type:
Seed investment

Ticker: BMRN – Market cap: 13.1 bln. USD

karobio-logo

Investment type:
Pre-IPO

Ticker: KARO – Market cap: 1.8 bln. SEK

QLT-logo

Investment type:
Public

Ticker: QLTI – Market cap: 75 mil. USD

nsgene-logo

Investment type:
Spin-Out (Co-lead investor)

Private

Acadia

Investment type:
Co-Founder

Ticker: ACAD – Market cap: 3.8 bln. USD

neurosearch-logo

Investment type:
Private

Ticker: NEUR – Market cap: 61.6 mil. DKK

Gyros_Logo_RGB-01

Investment type:
Spin-Out Stage

Private

zealand-big-logo

Investment type:
Seed-Investment

Ticker: ZEAL – Market cap: 3.0 bln. DKK

Bavarian_Nordic_logo.svg

Investment type:
Private

Ticker: BAVA – Market cap: 7.2 bln. DKK

AffyLogoTM_PMS.2

Investment type:
Public

Acquired by GSK for 533 mil. USD

idec-logo

Investment type:
Public

Merged with Biogen: BIIB – Market cap: 53.5 bln. USD

logo

Investment type:
Pro-management Activist Public Investment

Acquired by Abbott Laboratories Inc. for 450 mil. USD

logo-pyro

Investment type:
Private

Now Biotage: BIOT – Market cap: 2.0 bln. SEK

Pharmexa

Investment type:
Private

Merged with Affitech

OSI_Pharmaceuticals

Investment type:
Public

Acquired by Astellas Pharma for 4.0 bln. USD

The above stated investments were made by CEO Florian Schönharting at NB Capital in investment funds advised by NB Capital/Florian Schönharting or in his prior tenure at an asset management company. Note that some of them may have changed names since the point of investment. In this case the new name is listed.

Contact